Company intelligence / Profile preview

Akrikhin

Ownership: Private
Employees: ~208
Development stage: Commercial

Overview

Akrikhin is a leading Russian pharmaceutical company with a broad portfolio of more than 150 products across major therapeutic areas. The company operates at commercial scale with GMP-compliant manufacturing facilities near Moscow. It has a strategic partnership with Polpharma since 2007 for product development and technology transfer. Its medicines are widely recognized in Russia for quality and affordability. No specific clinical trial results are disclosed.

Therapeutic areas: CardiovascularEndocrinologyDermatologyOtherWomen's HealthNeurologyInfectious Diseases
Modalities: Small molecules (tablets, capsules, ointments, gels, creams, syrups)
Industry: Biotech

Drug pipeline

3 assets

Akrivario

2 more assets in the full pipeline.

Partnerships

Polpharma

Beyond the preview

Go deeper on Akrikhin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akrikhin.